(Q37822744)

23 August 2017

1 reference

title

Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens (English)

1 reference

23 August 2017

1 reference

1

0 references

author name string

Vrajesh V Parekh

series ordinal

2

1 reference

23 August 2017

Lan Wu

series ordinal

3

1 reference

23 August 2017

publication date

1 January 2011

1 reference

23 August 2017

1 reference

23 August 2017

volume

3

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

59-75

1 reference

Mechanisms maintaining peripheral tolerance.

23 August 2017

cites work

1 reference

The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

21 January 2018

1 reference

Toward an understanding of NKT cell biology: progress and paradoxes

21 January 2018

1 reference

CD1: antigen presentation and T cell function

21 January 2018

1 reference

21 January 2018

The biology of NKT cells

1 reference

Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities

21 January 2018

1 reference

NKT cells: what's in a name?

21 January 2018

1 reference

Antigen Presentation by CD1 Lipids, T Cells, and NKT Cells in Microbial Immunity

21 January 2018

1 reference

Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining

21 January 2018

1 reference

Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes.

21 January 2018

1 reference

Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers

21 January 2018

1 reference

In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers

21 January 2018

1 reference

The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion

21 January 2018

1 reference

Natural killer T cells within the liver: conductors of the hepatic immune orchestra

21 January 2018

1 reference

Phenotypic and functional differences between NKT cells colonizing splanchnic and peripheral lymph nodes.

21 January 2018

1 reference

Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography

21 January 2018

1 reference

CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection

21 January 2018

1 reference

To be or not to be NKT: natural killer T cells in the liver.

21 January 2018

1 reference

Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity.

21 January 2018

1 reference

Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection

21 January 2018

1 reference

Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population

21 January 2018

1 reference

Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia.

21 January 2018

1 reference

Going both ways: immune regulation via CD1d-dependent NKT cells

21 January 2018

1 reference

CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system

21 January 2018

1 reference

CD1d ligands: the good, the bad, and the ugly

21 January 2018

1 reference

Lipid and glycolipid antigens of CD1d-restricted natural killer T cells

21 January 2018

1 reference

iNKT cell autoreactivity: what is 'self' and how is it recognized?

21 January 2018

1 reference

Lysosomal glycosphingolipid recognition by NKT cells

21 January 2018

1 reference

Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d

21 January 2018

1 reference

Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals

21 January 2018

1 reference

Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency

21 January 2018

1 reference

Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation

21 January 2018

1 reference

Immunologic glycosphingolipidomics and NKT cell development in mouse thymus.

21 January 2018

1 reference

Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells

21 January 2018

1 reference

Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules.

21 January 2018

1 reference

Recognition of lyso-phospholipids by human natural killer T lymphocytes

21 January 2018

1 reference

Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia

21 January 2018

1 reference

Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.

21 January 2018

1 reference

Recognition of bacterial glycosphingolipids by natural killer T cells

21 January 2018

1 reference

Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells

21 January 2018

1 reference

Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria

21 January 2018

1 reference

A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan

21 January 2018

1 reference

Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells

21 January 2018

1 reference

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

21 January 2018

1 reference

CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution

21 January 2018

1 reference

Marine drugs from sponge-microbe association--a review

21 January 2018

1 reference

CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor

21 January 2018

1 reference

Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells

21 January 2018

1 reference

Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands

21 January 2018

1 reference

The in vivo response of invariant natural killer T cells to glycolipid antigens

21 January 2018

1 reference

Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo

21 January 2018

1 reference

Distinct functional lineages of human V(alpha)24 natural killer T cells

21 January 2018

1 reference

Differential antitumor immunity mediated by NKT cell subsets in vivo

21 January 2018

1 reference

Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency

21 January 2018

1 reference

Glycolipid antigen induces long-term natural killer T cell anergy in mice

21 January 2018

1 reference

NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge

21 January 2018

1 reference

Rapid NKT cell responses are self-terminating during the course of microbial infection.

21 January 2018

1 reference

Bacterial infection alters the kinetics and function of iNKT cell responses

21 January 2018

1 reference

Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy

21 January 2018

1 reference

Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease

21 January 2018

1 reference

A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma

21 January 2018

1 reference

Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

21 January 2018

1 reference

PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells

21 January 2018

1 reference

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

21 January 2018

1 reference

How do natural killer T cells help B cells?

21 January 2018

1 reference

Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis.

21 January 2018

1 reference

Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model.

21 January 2018

1 reference

CD1d-restricted help to B cells by human invariant natural killer T lymphocytes

21 January 2018

1 reference

Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers

21 January 2018

1 reference

Invariant NKT cells sustain specific B cell responses and memory

21 January 2018

1 reference

Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production

21 January 2018

1 reference

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection

21 January 2018

1 reference

CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies

21 January 2018

1 reference

A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells

21 January 2018

1 reference

Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides

21 January 2018

1 reference

Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide

21 January 2018

1 reference

Induction of Th1-biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells

21 January 2018

1 reference

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant

21 January 2018

1 reference

In vivo protection provided by a synthetic new alpha-galactosyl ceramide analog against bacterial and viral infections in murine models

21 January 2018

1 reference

Mechanisms for Glycolipid Antigen-Driven Cytokine Polarization by V 14i NKT Cells

21 January 2018

1 reference

Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen alphaGalCer

21 January 2018

1 reference

Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation

21 January 2018

1 reference

Activation of natural killer T cells by alpha-galactosylceramide mediates clearance of bacteria in murine urinary tract infection

21 January 2018

1 reference

Activation of NKT cells protects mice from tuberculosis.

21 January 2018

1 reference

Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection

21 January 2018

1 reference

alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria

21 January 2018

1 reference

Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans

21 January 2018

1 reference

Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection

21 January 2018

1 reference

NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus

21 January 2018

1 reference

Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells

21 January 2018

1 reference

Natural killer T cell activation inhibits hepatitis B virus replication in vivo.

21 January 2018

1 reference

Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis

21 January 2018

1 reference

Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.

21 January 2018

1 reference

NK T cell activation promotes Chlamydia trachomatis infection in vivo

21 January 2018

1 reference

Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial.

21 January 2018

1 reference

Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C.

21 January 2018

1 reference

Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants

21 January 2018

1 reference

Harnessing invariant NKT cells in vaccination strategies

21 January 2018

1 reference

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines

21 January 2018

1 reference

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

21 January 2018

1 reference

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system

21 January 2018

1 reference

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.

21 January 2018

1 reference

Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.

21 January 2018

1 reference

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide

21 January 2018

1 reference

Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin

21 January 2018

1 reference

Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

21 January 2018

1 reference

Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells

21 January 2018

1 reference

The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation

21 January 2018

1 reference

Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide

21 January 2018

1 reference

Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice

21 January 2018

1 reference

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

21 January 2018

1 reference

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer

21 January 2018

1 reference

Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy

21 January 2018

1 reference

Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells

21 January 2018

1 reference

Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells

21 January 2018

1 reference

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

21 January 2018

1 reference

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

21 January 2018

1 reference

Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.

21 January 2018

1 reference

A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.

21 January 2018

1 reference

Natural killer T cell-mediated immunotherapy for malignant diseases

21 January 2018

1 reference

Adjuvant activity mediated by iNKT cells

21 January 2018

1 reference

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets

21 January 2018

1 reference

CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes

21 January 2018

1 reference

Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette

21 January 2018

1 reference

Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells.

21 January 2018

1 reference

Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice

21 January 2018

1 reference

An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.

21 January 2018

1 reference

alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles

21 January 2018

1 reference

Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis

21 January 2018

1 reference

Invariant NKT cells inhibit development of the Th17 lineage

21 January 2018

1 reference

Beta-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus

21 January 2018

1 reference

Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids

21 January 2018

1 reference

NKT cells: manipulable managers of joint inflammation.

21 January 2018

1 reference

Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide

21 January 2018

1 reference

A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner.

21 January 2018

1 reference

NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor beta1 production

21 January 2018

1 reference

Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses

21 January 2018

1 reference

The role of invariant natural killer T cells in lupus and atherogenesis

21 January 2018

1 reference

Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus

21 January 2018

1 reference

The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice

21 January 2018

1 reference

Regulatory roles for NKT cell ligands in environmentally induced autoimmunity

21 January 2018

1 reference

Schistosoma mansoni and alpha-galactosylceramide: prophylactic effect of Th1 Immune suppression in a mouse model of Graves' hyperthyroidism

21 January 2018

1 reference

Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules

21 January 2018

1 reference

CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity

21 January 2018

1 reference

Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells

21 January 2018

1 reference

alpha-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation

21 January 2018

1 reference

Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide.

21 January 2018

1 reference

A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity

21 January 2018

1 reference

Plasticity of invariant NKT cell regulation of allergic airway disease is dependent on IFN-gamma production

21 January 2018

1 reference

CD1d-dependent activation of NKT cells aggravates atherosclerosis.

21 January 2018

1 reference

Natural killer T cells accelerate atherogenesis in mice

21 January 2018

1 reference

Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity.

21 January 2018

1 reference

Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen

21 January 2018

1 reference

Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets.

21 January 2018

1 reference

Host-residual invariant NK T cells attenuate graft-versus-host immunity

21 January 2018

1 reference

Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration

21 January 2018

1 reference

Involvement of decidual Valpha14 NKT cells in abortion

21 January 2018

1 reference

Clinical applications of natural killer T cell-based immunotherapy for cancer

21 January 2018

1 reference

The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids

21 January 2018

1 reference

α-GalCer ameliorates listeriosis by accelerating infiltration of Gr-1+ cells into the liver

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.10.85

1 reference

23 August 2017

1 reference